- Assembly of recognized experts to bring complementary
experience and insights to Rockley’s ongoing efforts to
revolutionize wearable biosensing technology
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced the formation of a
scientific advisory board (SAB) gathering world-renowned experts
across several key disciplines in biomedical science and
technology, including spectroscopy, diabetes technology, hydration
science, and cardiology.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220810005273/en/
Rockley’s new scientific advisory board
(Graphic: Business Wire)
The newly formed SAB will support Rockley’s mission of
empowering people to make better-informed decisions about their
health and well-being. The members of the SAB will advise Rockley
concerning its unique biosensing platform, which enables the
non-invasive, continuous, and near-real-time monitoring of multiple
biomarkers. The members will provide input, guidance, and support
for Rockley’s efforts to realize the full potential of its
biosensing platform for the consumer and medtech markets.
The SAB will be chaired by Vish Kulkarni, senior vice president
of commercial at Rockley Photonics. The initial members of the
Rockley SAB include the following experts in their field:
Mark A. Arnold, Ph.D. is the
Edwin B. Green Chair in Laser Chemistry, professor of chemistry and
director of the Center for Biocatalysis and Bioprocessing (CBB) at
the University of Iowa. He is a widely recognized expert in the
non-invasive optical monitoring of biomarkers such as glucose and
urea. In 2016, Dr. Arnold received the Senior Spectroscopist
Designation from the Society for Applied Spectroscopy. He has been
the Fellow of the Society for Applied Spectroscopy since 2010 and
was a collegiate fellow at the College of Liberal Arts and
Sciences, University of Iowa from 2001 to 2006.
Zahi A. Fayad, Ph.D. is a professor of
Radiology and Medicine (cardiology) at the Icahn School of Medicine
at Mount Sinai and holds the Lucy G. Moses Professorship in Medical
Imaging and Bioengineering at the Icahn School of Medicine in New
York. He is the founding director of Mount Sinai’s Biomedical
Engineering and Imaging Institute and vice chair for research in
the Department of Radiology at the Icahn School of Medicine at
Mount Sinai. Dr. Fayad’s interdisciplinary and discipline-bridging
research — from engineering to biology and from pre-clinical to
clinical investigations — has been dedicated to the detection and
prevention of cardiovascular disease, with many seminal
contributions in the field of multimodality biomedical imaging,
nanomedicine, AI/ML in Imaging, and digital mobile health. Dr.
Fayad is a paid consultant for Rockley Photonics.
Stavros Kavouras, Ph.D. is an
assistant dean of graduate education and professor of nutrition at
Arizona State University. He directs the Hydration Science Lab,
where he is studying the mechanisms by which water intake can
impact health and performance. His current research focuses on the
effect of water intake on glucose regulation and its implication on
children’s hydration and obesity. Dr. Kavouras has authored more
than 150 peer-review articles and 9,000 citations and has given
lectures in 29 countries.
David C. Klonoff, M.D. is an
endocrinologist specializing in the development and use of diabetes
technology. He is the medical director of the Dorothy L. and James
E. Frank Diabetes Research Institute of Mills-Peninsula Medical
Center in San Mateo, California, and is a Clinical Professor of
Medicine at University of California San Francisco. Dr. Klonoff
received the American Diabetes Association’s Outstanding Physician
Clinician Award in 2019. He received an FDA Director’s Special
Citation Award from the U.S. Food and Drug Administration in 2010
for outstanding contributions related to diabetes technology. In
2012, Dr. Klonoff was elected to the College of Fellows at the
American Institute of Medical and Biological Engineering (AIMBE),
representing the top 2% of the world’s medical and biological
engineers. He is founding editor of the Journal of Diabetes Science
and Technology.
Vish Kulkarni, senior vice president of commercial at Rockley
Photonics, said, “This esteemed group brings a diverse range of
skills and experiences to the Rockley community, from scientific
and medical expertise to the commercial application of biomedical
technology. The willingness of these distinguished individuals to
join our advisory board reinforces the importance and relevance of
Rockley’s work in wearable biosensing technology. We look forward
to working with them, and to adding new members to this advisory
board, as we drive our efforts to meet the fast-growing demand for
better insights into personal health and well-being.”
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/biomarker-sensing/.
About Rockley Photonics A global leader in photonics-based
health monitoring and communications solutions, Rockley Photonics
is developing a comprehensive range of photonic integrated circuits
and associated modules, sensors, and full-stack solutions. From
next-generation sensing platforms specifically designed for mobile
health monitoring and machine vision to high-speed, high-volume
solutions for data communications, Rockley is laying the foundation
for a new generation of applications across multiple industries.
Rockley believes that photonics will eventually become as pervasive
as micro-electronics, and it has developed a platform with the
power and flexibility needed to address both mass markets and a
wide variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements Statements
in this press release that are not historical facts constitute
“forward-looking statements” for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include statements regarding
Rockley’s future expectations, beliefs, plans, objectives, and
assumptions regarding future events or performance. The words
“accelerate,” “advance,” “anticipate,” “believe,” “can,”
“capability,” “continue,” “could,” “develop,” “enable,” “estimate,”
“eventual,” “expand, “expect,” “focus,” “forward,” “future,”
“goal,” “intend,” “may,” “might,” “opportunity,” “outlook,” “plan,”
“possible,” “position,” “potential,” “predict,” “project,”
“revolutionize,” “seem,” “should,” “trend,” “vision,” “will,”
“would” or other terms that predict or indicate future events,
trends, or expectations, and similar expressions or the negative of
such expressions may identify forward-looking statements, but the
absence of these words or terms does not mean that a statement is
not forward-looking. Forward-looking statements in this press
release include, but are not limited to, statements regarding the
following: (a) the potential of Rockley’s sensing platform to
provide non-invasive, continuous, near-real-time monitoring of
biomarkers that provide insights about a variety of health
conditions; (b) the anticipated and potential features, scope,
goals, and benefits of the Company’s platform, products, and
technology; (c) its development of a range of photonic integrated
circuits and associated modules, sensors, and full-stack solutions;
(d) Rockley’s belief that photonics will eventually become as
pervasive as micro-electronics; and (e) Rockley’s potential to
support hyper-scale manufacturing, address a multitude of
high-volume markets, and deliver the complex optical systems
required to bring transformational products to market.
Forward-looking statements are subject to several risks,
assumptions, and uncertainties (many of which are beyond Rockley’s
control) that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the factors described under the heading “Risk Factors”
in Rockley’s Annual Report on Form 10-K for the year ended December
31, 2021, and in other documents Rockley files with the Securities
and Exchange Commission. If any of these risks or uncertainties
materialize, or should any of these assumptions prove incorrect,
actual results may differ materially from those discussed in or
implied by these forward-looking statements. There can be no
assurance that future developments affecting Rockley will be those
that have been anticipated. Given these risks and uncertainties,
you should not place undue reliance on these forward-looking
statements. These forward-looking statements speak only as of the
date hereof and Rockley does not intend to update or revise any
forward-looking statements, whether because of new information,
future events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220810005273/en/
Media Debra Raine Rainemakers Telephone: +1 415-349-7432 Email:
rockleyphotonics@rainemakers.com Investors Gwyn Lauber Rockley
Photonics Telephone: +1 626-995-0001 Email:
investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Rockley Photonics (NYSE:RKLY)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
